SecBot SecBot
SECBOTREPLAY Home › Report › AXGN

AXGN · Axogen priced an underwritten public offering of 4,910,000 shares at…

Axogen, Inc. · PRESS-RELEASE filed Sep 10, 2026 at 06:01 ET

At the news

BEARISHIMPACT 6/10

PRESS-RELEASE filed Sep 10, 2026 at 06:01 ET

Axogen priced an underwritten public offering of 4,910,000 shares at $42.50 per share, expected to raise ~$208.7M in gross proceeds. The funds are primarily earmarked to finance the cash consideration for the previously announced BioCircuit Technologies acquisition, with any remainder for general corporate purposes. The offering is not conditioned on the acquisition closing, creating a scenario where Axogen could hold a large cash balance if the deal falls through, but the immediate effect is significant dilution for existing shareholders.

  • Pricing of 4,910,000 shares at $42.50 per share in an underwritten public offering.
  • Gross proceeds expected to be approximately $208.7 million.
  • Underwriters granted a 30-day option to purchase up to an additional 736,500 shares.
  • Net proceeds primarily intended to fund the cash consideration for the BioCircuit Technologies acquisition.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access